Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-term, Open-label, Flexible-dose, Continuation Extension Study With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of Age

NCT03108625 is registered in ClinicalTrials.gov with H. Lundbeck A/S as lead sponsor.

NCT NCT03108625
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03108625 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-term, Open-label, Flexible-dose, Continuation Extension Study With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of Age
Lead sponsor
H. Lundbeck A/S
Phase
Phase 3
Overall status
Completed
Start date
March 1, 2017
Completion date
April 16, 2020
Enrollment
94 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

depressive disorder, major